Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Spark Capital Advisors(India) Private Limited
$35.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aurobindo Pharma Ltd Receives Final Approvals For Felodipine Extended-Release Tablets


Friday, 18 Jan 2013 02:43am EST 

Aurobindo Pharma Ltd announced that the Company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Felodipine Extended-release Tablets USP 2.5mg, 5mg, and 10mg. (ANDA 203417). Felodipine Extended-release Tablets USP 2.5mg, 5mg, and 10mg is the generic equivalent of AstraZeneca‚Äôs Plendil Extended-release Tablets, 2.5mg, 5mg and 10mg and indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. The annual sale of the product is approximately USD 64 million for the twelve months ending March 2012 according to IMS. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India 

Company Quote

1091.6
 --
24 Dec 2014